Logo image of CATX

PERSPECTIVE THERAPEUTICS INC (CATX) Stock Overview

USA - NYSEARCA:CATX - US46489V3024 - Common Stock

4.86 USD
+1 (+25.91%)
Last: 10/10/2025, 9:13:59 PM
4.7 USD
-0.16 (-3.29%)
After Hours: 10/10/2025, 9:13:59 PM

CATX Key Statistics, Chart & Performance

Key Statistics
52 Week High13.19
52 Week Low1.6
Market Cap360.90M
Shares74.26M
Float60.25M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1
PEN/A
Fwd PEN/A
Earnings (Next)12-15 2025-12-15/amc
IPO05-31 2002-05-31
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CATX short term performance overview.The bars show the price performance of CATX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100

CATX long term performance overview.The bars show the price performance of CATX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 -50

The current stock price of CATX is 4.86 USD. In the past month the price increased by 39.66%. In the past year, price decreased by -61.61%.

PERSPECTIVE THERAPEUTICS INC / CATX Daily stock chart

CATX Latest News, Press Relases and Analysis

CATX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.77 407.19B
AMGN AMGEN INC 13.3 156.19B
GILD GILEAD SCIENCES INC 15.14 145.40B
VRTX VERTEX PHARMACEUTICALS INC 24.07 104.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.36B
REGN REGENERON PHARMACEUTICALS 12.37 59.85B
ARGX ARGENX SE - ADR 85.97 48.77B
ONC BEONE MEDICINES LTD-ADR 5.17 35.16B
INSM INSMED INC N/A 34.31B
BNTX BIONTECH SE-ADR N/A 24.54B
NTRA NATERA INC N/A 23.23B
BIIB BIOGEN INC 9.15 21.49B

About CATX

Company Profile

CATX logo image Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Seattle, Washington and currently employs 138 full-time employees. The company went IPO on 2002-05-31. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Company Info

PERSPECTIVE THERAPEUTICS INC

2401 Elliott Avenue, Suite 320

Seattle WASHINGTON US

Employees: 139

CATX Company Website

CATX Investor Relations

Phone: 12066760900

PERSPECTIVE THERAPEUTICS INC / CATX FAQ

What is the stock price of PERSPECTIVE THERAPEUTICS INC today?

The current stock price of CATX is 4.86 USD. The price increased by 25.91% in the last trading session.


What is the ticker symbol for PERSPECTIVE THERAPEUTICS INC stock?

The exchange symbol of PERSPECTIVE THERAPEUTICS INC is CATX and it is listed on the NYSE Arca exchange.


On which exchange is CATX stock listed?

CATX stock is listed on the NYSE Arca exchange.


What is the price forecast or stock price prediction for PERSPECTIVE THERAPEUTICS INC stock?

19 analysts have analysed CATX and the average price target is 13.73 USD. This implies a price increase of 182.52% is expected in the next year compared to the current price of 4.86. Check the PERSPECTIVE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PERSPECTIVE THERAPEUTICS INC worth?

PERSPECTIVE THERAPEUTICS INC (CATX) has a market capitalization of 360.90M USD. This makes CATX a Small Cap stock.


How many employees does PERSPECTIVE THERAPEUTICS INC have?

PERSPECTIVE THERAPEUTICS INC (CATX) currently has 139 employees.


What are the support and resistance levels for PERSPECTIVE THERAPEUTICS INC (CATX) stock?

PERSPECTIVE THERAPEUTICS INC (CATX) has a support level at 3.36. Check the full technical report for a detailed analysis of CATX support and resistance levels.


Is PERSPECTIVE THERAPEUTICS INC (CATX) expected to grow?

The Revenue of PERSPECTIVE THERAPEUTICS INC (CATX) is expected to decline by -17.6% in the next year. Check the estimates tab for more information on the CATX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PERSPECTIVE THERAPEUTICS INC (CATX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PERSPECTIVE THERAPEUTICS INC (CATX) stock pay dividends?

CATX does not pay a dividend.


When does PERSPECTIVE THERAPEUTICS INC (CATX) report earnings?

PERSPECTIVE THERAPEUTICS INC (CATX) will report earnings on 2025-12-15, after the market close.


What is the Price/Earnings (PE) ratio of PERSPECTIVE THERAPEUTICS INC (CATX)?

PERSPECTIVE THERAPEUTICS INC (CATX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1).


What is the Short Interest ratio of PERSPECTIVE THERAPEUTICS INC (CATX) stock?

The outstanding short interest for PERSPECTIVE THERAPEUTICS INC (CATX) is 11.07% of its float. Check the ownership tab for more information on the CATX short interest.


CATX Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to CATX. When comparing the yearly performance of all stocks, CATX is a bad performer in the overall market: 86.89% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CATX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CATX. The financial health of CATX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CATX Financial Highlights

Over the last trailing twelve months CATX reported a non-GAAP Earnings per Share(EPS) of -1. The EPS increased by 39.76% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -30.56%
ROE -35.74%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-61.11%
Sales Q2Q%-44.87%
EPS 1Y (TTM)39.76%
Revenue 1Y (TTM)-72.37%

CATX Forecast & Estimates

19 analysts have analysed CATX and the average price target is 13.73 USD. This implies a price increase of 182.52% is expected in the next year compared to the current price of 4.86.

For the next year, analysts expect an EPS growth of -43.54% and a revenue growth -17.6% for CATX


Analysts
Analysts81.05
Price Target13.73 (182.51%)
EPS Next Y-43.54%
Revenue Next Year-17.6%

CATX Ownership

Ownership
Inst Owners58.73%
Ins Owners3.02%
Short Float %11.07%
Short Ratio9.15